Article
Increased CGT demand could fuel demand for alternative cleanroom arrangements
Ravi Samavedam
In this Drug Discovery & Development article, you will gain insight into the evergrowing life sciences market and how to stay on top of the increased demand in the years to come.
“Keeping up with market forces will require an increase in demand for therapies that will outstrip current means of production. Building facilities requires validation that can delay the manufacturing process while CDMOs are already operating at capacity. Neither alternative will satisfy growing demand.”
- Ravi Samavedam, Chief Innovation Officer at Azzur Group
Read the full article featured on Drug Discovery & Development or learn more about how Azzur's Cleanrooms on Demand™ hybrid model is accommodating the growth of the cell and gene therapy market.
Ravi Samavedam
Ravi Samavedam joined Azzur Group in 2012 and is a Biochemical Engineer with more than 20 years of experience. Prior to his appointment to Chief Innovation Officer (CINO), Ravi served as President of Azzur Cleanrooms on Demand™ and previously was a General Manager of Azzur Boston. Ravi has been a part of technical operations, quality, and validation departments at some of the world’s foremost pharmaceutical manufacturers. He is an expert in phase-appropriate cGMP implementation, process validation, supplier management, and technology transfer. Ravi is an active member of industry and peer groups, and he is a frequent speaker at industry events.
Connect On Linkedin